Globally, gastric cancer is the fourth most commonly occurring cancer ([@bib19]), with variable overall survival rates; the 5-year survival rate ranges from 10--30% in most of the world to 50--70% in Korea and Japan ([@bib25]; [@bib35]; [@bib30]; [@bib14]). Although surgical resection of localised gastric tumours offers a potentially curative therapy, most patients present with inoperable, advanced or metastatic disease requiring palliative treatment ([@bib16]), with the exception of some countries in East Asia, such as Korea and Japan, where national screening programmes are conducted ([@bib16]; [@bib31]). Combining multiple chemotherapy agents has improved overall survival rates compared with single agents or best supportive care ([@bib43]), and the current standard chemotherapy regimen for patients with advanced gastric cancer (aGC) contains a fluoropyrimidine plus a platinum compound ([@bib29]). However, the prognosis of patients with aGC remains poor and improved treatment options are required for this disease.

Human epidermal growth factor receptor 2 (HER2) overexpression/amplification is an established negative prognostic biomarker in breast cancer and occurs in ∼20% of cases ([@bib39], [@bib40]), whereas 17--22% of gastric cancer cases have been reported to be HER2-positive ([@bib42]; [@bib33]; [@bib46]; [@bib5]). In the phase III ToGA trial, the addition of the HER2-targeted humanised monoclonal antibody trastuzumab to first-line fluoropyrimidine plus cisplatin chemotherapy significantly increased overall survival in patients with HER2-positive advanced gastric or gastro--oesophageal junction cancer, with further survival benefit in patients whose tumours had high levels of HER2 expression (immunohistochemistry (IHC) 3+ or IHC 2+ and fluorescence *in situ* hybridisation-positive; [@bib5]). The grade 3--4 adverse event (AE) profiles were similar between the trastuzumab plus chemotherapy arm and the chemotherapy-only arm, with the exception of increased rates of diarrhoea in patients receiving trastuzumab ([@bib5]). On the basis of the data from the ToGA trial, trastuzumab was approved in combination with capecitabine plus cisplatin or 5-fluorouracil plus cisplatin for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach or gastro--oesophageal junction ([@bib27]). Lapatinib, an oral tyrosine kinase inhibitor of epidermal growth factor receptor and HER2, has also been tested in HER2-positive gastric cancer. However, lapatinib did not improve overall survival when combined with chemotherapy for first-line ([@bib26]) or second-line treatment ([@bib6]) of HER2-positive aGC.

Pertuzumab is a humanised monoclonal antibody that targets a different epitope of HER2 from trastuzumab ([@bib11]; [@bib20]). Whereas trastuzumab binds to subdomain IV of HER2 ([@bib11]) to inhibit ligand-independent signalling ([@bib32]), pertuzumab binds to subdomain II ([@bib20]), the dimerisation domain, to inhibit HER2 heterodimerisation and, consequently, ligand-dependent signalling ([@bib2]). Pre-clinical studies have suggested that trastuzumab and pertuzumab have complementary mechanisms of action and that the combination of the two antibodies provides a more efficient blockade of HER2 signalling than either antibody alone ([@bib36]; [@bib37]). In the CLEOPATRA study of patients with HER2-positive metastatic breast cancer (MBC), the combination of pertuzumab, trastuzumab and docetaxel significantly improved progression-free ([@bib7]) and overall survival ([@bib41]) compared with placebo, trastuzumab and docetaxel. Furthermore, pre-clinical studies of a HER2-positive human gastric cancer xenograft model showed enhanced anti-tumour activity when pertuzumab and trastuzumab were combined, compared with that seen with either antibody alone ([@bib44]). Therefore, the combination of pertuzumab with trastuzumab and chemotherapy has the potential to improve survival outcomes in patients with HER2-positive aGC compared with trastuzumab and chemotherapy alone.

In patients with HER2-positive aGC, the observed steady-state exposure of trastuzumab was lower than that seen with an identical dose in MBC, and patients with trastuzumab concentrations in the lowest quartile had a shorter median overall survival (7.7 (range, 6.3--10.6) months) than patients in the upper three quartiles (15.7 (range, 14.1--18.9) months; [@bib45]). Furthermore, in a separate analysis, patients with the lowest trastuzumab serum trough concentrations had the highest rate of disease progression and shortest overall survival ([@bib13]). Therefore, we aimed to study the pharmacokinetics (PK) of pertuzumab in combination with trastuzumab and chemotherapy to identify the pertuzumab dose that produces a steady-state trough serum concentration (*C*~min~) of ⩾20 *μ*g ml^−1^ in at least 90% of patients with HER2-positive gastric cancer. This PK target was derived from dose-response xenograft studies of pertuzumab administered as a single agent showing effective tumour-growth inhibition with serum trough concentrations of 5--25 *μ*g ml^−1^ ([@bib34]), and is also the PK target that was used to determine the pertuzumab dose in breast cancer. In patients with HER2-positive breast cancer, the PK target was achieved with a pertuzumab loading dose of 840 mg followed by 420 mg q3w, a dosing regimen that has shown promising activity in early and advanced breast cancer treatment settings ([@bib8]; [@bib12]; [@bib22]; [@bib38]; [@bib41]). Importantly, phase I/II trials of both weight-based and fixed pertuzumab doses in multiple tumour types have not revealed a maximum tolerated dose ([@bib1]; [@bib4]; [@bib3]). Here we present the results of JOSHUA, a phase IIa study of the PK and safety of two different doses of pertuzumab in combination with trastuzumab and chemotherapy, to identify the optimal pertuzumab dose for clinical studies in HER2-positive gastric cancer.

Materials and methods
=====================

Study design and treatment
--------------------------

JOSHUA was a randomised, multicentre, open-label phase IIa trial (NCT01461057) evaluating two different doses of pertuzumab in patients with HER2-positive advanced gastric or gastro--oesophageal junction cancer. Treatment was given in 3-weekly cycles. Patients were randomised to receive an initial pertuzumab dose of 840 mg for cycle 1, followed by a dose of 420 mg for cycles 2--6 (Arm A) or pertuzumab 840 mg for cycles 1--6 (Arm B). Patients in both treatment arms received cisplatin (80 mg m^−2^) and capecitabine (1000 mg m^−2^ BID for 14 days) for cycles 1--6; in the absence of disease progression or unmanageable toxicity, patients could receive capecitabine for more than six cycles, at the discretion of the investigator. All patients received trastuzumab at 8 mg kg^−1^ for cycle 1, followed by 6 mg kg^−1^ for subsequent cycles, until investigator-assessed disease progression or unmanageable toxicity. The study was approved by the institutional review board of each participating centre or the competent authority and ethics committee. The study was conducted in full accordance with the International Conference on Harmonisation Good Clinical Practice guidelines and the Declaration of Helsinki. All patients provided written informed consent.

The co-primary endpoints of the study were *C*~min~ at day 43 (cycle 2 trough concentration) and safety. The aim of the PK endpoint was to identify the pertuzumab dose that produced a steady-state *C*~min~ of ⩾20 *μ*g ml^−1^ in at least 90% of patients. The aim of the safety endpoint was to assess the incidence of all AEs. An exploratory objective of the study was to assess the anti-tumour activity of pertuzumab in combination with trastuzumab and chemotherapy in this disease setting.

Patient population
------------------

Patients ⩾18 years old were eligible if they had histologically confirmed, inoperable, locally advanced or metastatic HER2-positive adenocarcinoma of the stomach or gastro--oesophageal junction. HER2 positivity was defined as IHC 3+ or IHC 2+ and *in situ* hybridisation (ISH)-positive (ISH positivity was defined as a *HER2 *: *CEP17* signal ratio of ⩾2.0) by central testing. Eligible patients had measurable disease or non-measurable, evaluable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 ([@bib18]). Patients were required to have an Eastern Cooperative Oncology Group performance status of 0 or 1, a baseline left ventricular ejection fraction (LVEF) of ⩾55% and a life expectancy of ⩾3 months. Patients were eligible if they had not received prior treatment for advanced or metastatic disease; prior (neo)adjuvant therapy was allowed if completed ⩾6 months before study enrolment, whereas platinum-based (neo)adjuvant therapy was prohibited. Patients were not eligible for the study if they had a serious cardiac illness or medical condition.

Analysis of PK
--------------

For pertuzumab PK assessment, pre-dose and post-dose serum samples were collected at cycles 1, 2, 3, 4 and 6. Pre-dose samples were collected up to 6 h before the administration of pertuzumab and post-dose samples were collected up to 30 min after the pertuzumab infusion. The cycle 2 trough (cycle 3 pre-dose) sample had to be collected on study day 43 (21 days after the cycle 2 dose), regardless of whether the cycle 3 dose was given, delayed or not given. In addition, weekly serum samples were collected in cycles 1 and 2. A validated bridging enzyme-linked immunosorption assay was used to measure the concentration of pertuzumab in serum samples. The assay used a monoclonal anti-idiotype antibody to capture pertuzumab and had a minimum quantifiable concentration in human serum of 150 ng ml^−1^.

Assessments
-----------

For tumour response assessments, all measurable and non-measurable, evaluable disease had to be documented at screening and reassessed at the end of cycles 3 and 6 according to RECIST v1.1, after which patients were followed for tumour response according to local standards. Response was assessed by the investigator based on physical examinations, computed tomography scans or magnetic resonance imaging. Other methods were allowed if they were amenable to evaluation per RECIST.

LVEF assessments by echocardiogram or multiple-gated acquisition scan were performed at baseline and then every three cycles until disease progression or treatment discontinuation. LVEF assessments were performed at the treatment discontinuation visit, every 6 months for the first year following treatment discontinuation, then annually for up to 3 years following treatment discontinuation. Patients who discontinued study treatment permanently due to LVEF decline continued to have LVEF assessments repeated as clinically indicated, with a maximum interval of 3 months between assessments, until LVEF returned to \>50%, or 1 year after the treatment discontinuation visit, whichever occurred first. Thereafter, LVEF assessments were performed annually for up to 3 years after the treatment discontinuation visit.

AEs were graded according to The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0 (National Cancer Institute, Bethesda, MD, USA). Real-time safety monitoring occurred on an ongoing basis for all patients and expedited reporting was performed for serious AEs and AEs of special interest. AEs and serious AEs were recorded throughout the study and up to 6 months after the last dose of study treatment, with the exception of cardiac AEs, which were followed for 12 months after the last dose of study treatment, and symptomatic LVEF, which was required to be reported up to 3 years after the last dose of study treatment. Study drug-related serious AEs continued to be recorded regardless of the time elapsed since the last dose of study treatment.

Statistical analysis
--------------------

A sample size of 15 patients per arm was considered sufficient to determine the dose needed to achieve the target *C*~min~ with an acceptable degree of precision (coefficient of variation \<15%). This was determined based on trastuzumab PK data from the ToGA trial and the assumption that pertuzumab behaves similarly to trastuzumab in aGC. However, due to variability, outliers and the limited number of data points due to patient withdrawals, it was not possible to accurately assess the primary PK endpoint on the basis of the observed percentage of patients who achieved the target *C*~min~. Therefore, a *post hoc* bootstrap analysis was conducted to estimate the percentage of patients at or above the target *C*~min~ and the confidence interval (CI) of this estimate (analysis performed in R Statistics Software version 2.10.1, R Foundation for Statistical Computing, Vienna, Austria). For each pertuzumab dose group, a sample of 15 patients was generated on the basis of the mean and s.d. of the observed data assuming a log-normal distribution, and the percentage of patients with a pertuzumab *C*~min~ of ⩾20 *μ*g ml^−1^ was computed. The process was repeated 1000 times to generate an estimated percentage of patients with a pertuzumab *C*~min~ of ⩾20 *μ*g ml^−1^ and a 95% CI.

Results
=======

Patient and disease characteristics
-----------------------------------

Between December 2011 and April 2012, 30 patients enroled into the study and 15 were randomised into each arm. The baseline demographics and disease characteristics of patients were generally well balanced between arms, although there were some imbalances in terms of age and sex, with older patients and more men in Arm A ([Table 1](#tbl1){ref-type="table"}). The majority of patients had metastatic gastric cancer.

The data cutoff occurred on 31 December 2012, at which point the mean follow-up time was 312 days and 260 days in Arms A and B, respectively. Fourteen patients in Arm A and 11 patients in Arm B had received all six cycles of pertuzumab ([Table 2](#tbl2){ref-type="table"}). Seven patients in Arm A and three patients in Arm B were still receiving study treatment while the remaining patients had discontinued: eight patients in Arm A (due to disease progression) and 12 patients in Arm B (eight due to disease progression, one due to an AE (worsening renal failure), one at the physician\'s decision (due to pneumonia), one death (fungal pneumonia) and one withdrawal by the patient).

PK of pertuzumab
----------------

Mean pertuzumab serum concentration--time profiles are shown in [Figure 1](#fig1){ref-type="fig"}. Pertuzumab concentrations were similar between arms at cycle 1 (when the dose was the same for each arm). However, from cycle 2 onwards, pertuzumab concentrations were higher in Arm B than in Arm A, consistent with the higher dose in Arm B. In Arm A, the mean pertuzumab *C*~min~ increased ∼2-fold from day 22 to day 106, whereas in Arm B the increase in mean pertuzumab *C*~min~ over this time was slightly higher, at ∼2.9-fold. Overall, pertuzumab concentrations were dose proportional.

Fifteen patients in Arm A and 13 patients in Arm B had data available to assess pertuzumab *C*~min~ at day 43. One patient in Arm B had abnormally low pertuzumab concentrations, with a day 22 *C*~min~ below the assay\'s lower limit of quantification and a day 43 *C*~min~ of 0.610 *μ*g ml^−1^. After excluding this patient from the analysis, the day 43 mean (s.d.) pertuzumab *C*~min~ in Arms A and B was 40.0 *μ*g ml^−1^ (17.3) and 62.7 *μ*g ml^−1^ (29.1), respectively, and the geometric mean *C*~min~ in Arms A and B was 36.8 *μ*g ml^−1^ and 56.4 *μ*g ml^−1^, respectively.

Summary box-scatter plots in [Figure 2](#fig2){ref-type="fig"} show the day 43 pertuzumab *C*~min~ values observed in this study and in the pertuzumab arm of the CLEOPATRA trial, which studied HER2-positive MBC. Mean pertuzumab *C*~min~ with the 840/420 mg dose in HER2-positive aGC (Arm A) was ∼37% lower than that observed with the same dose in HER2-positive MBC (in CLEOPATRA). Mean pertuzumab *C*~min~ with the 840 mg q3w dose in HER2-positive aGC (Arm B) was similar to that observed with the 840/420 mg dose in HER2-positive MBC.

As day 43 pertuzumab *C*~min~ samples from Arm B were only available for 12 patients, the ability to select the most appropriate pertuzumab dose based on the observed data was limited. Therefore, a bootstrap analysis was conducted to estimate the percentage of patients who achieved the target pertuzumab *C*~min~ of ⩾20 *μ*g ml^−1^ at day 43 and the CI of this estimate. This analysis showed that 91.6% (95% CI 78.3, 99.2) and 98.3% (95% CI 91.4, 99.97) of patients in Arms A and B, respectively, achieved the target *C*~min~.

Safety
------

At the time of data cutoff, patients in Arm A had received a median of six (range, 4--6) doses of pertuzumab and patients in Arm B had received a median of six (range, 1--6) doses of pertuzumab. Overall, the AE profiles were similar between arms. Diarrhoea was the most common AE and was mostly grade 1--2; onset was in cycle 1, with the frequency decreasing during subsequent cycles. [Figure 3](#fig3){ref-type="fig"} shows the incidence of diarrhoea at each treatment cycle. No patient discontinued therapy due to diarrhoea. There were 24 reports (16 in Arm A and 8 in Arm B) of grade ⩾2 diarrhoea in 18 patients (11 in Arm A and 7 in Arm B). Onset of the first incidence of grade ⩾2 diarrhoea in these patients occurred on median (range) study day 12 (1--237) (study day 13 (6--237) in Arm A, study day 8 (1--16) in Arm B). There were 13 instances (8 in Arm A (in seven patients) and 5 in Arm B (in three patients)) of capecitabine dose reduction due to an AE that occurred either during the duration of grade ⩾2 diarrhoea or on day 1 of the subsequent treatment cycle, following resolution of grade ⩾2 diarrhoea. For these 10 patients, initial capecitabine dose reduction occurred on median (range) study day 35.5 (22--181) (study day 42 (23--181) in Arm A, study day 22 (22--56) in Arm B).

The total number of grade ⩾3 AEs was 78 in Arm A and 60 in Arm B and the most frequent grade ⩾3 AEs are shown in [Table 3](#tbl3){ref-type="table"}. Seventy-three percent and 67% of patients in Arms A and B, respectively, experienced at least one serious AE and the total number of all serious AEs was 35 in Arm A and 19 in Arm B. Serious AEs that occurred in ⩾2 patients overall were diarrhoea, febrile neutropenia, acute renal failure, asthenia, fatigue, gastric obstruction, hyponatraemia, mucosal inflammation, neutropenia, pneumonia, pulmonary embolism and vomiting. One serious AE in Arm B (fungal pneumonia) resulted in death. This was considered by the investigator to be related to the chemotherapy agents. No patient experienced symptomatic heart failure. Two patients, both in Arm A, experienced asymptomatic LVEF decline. After delaying study treatment, their LVEF values recovered and these patients continued receiving study treatment.

Overall response
----------------

An exploratory endpoint of the study was to assess the anti-tumour activity of pertuzumab with trastuzumab, cisplatin and capecitabine in patients with HER2-positive aGC ([Table 4](#tbl4){ref-type="table"}). At the end of cycle 3, 10 (67%) and 7 (58%) patients in Arms A and B, respectively, had achieved a partial response, whereas an additional 4 patients in each arm (27% and 33%, respectively) had stable disease. One patient in each arm had progressive disease. At the end of cycle 6, a partial response was observed in 12 (86%) and 6 (55%) patients in Arms A and B, respectively, whereas 2 (14%) and 3 (27%) patients, respectively, had stable disease. Two patients in Arm B had progressive disease.

Discussion
==========

The primary objective of this study was to identify the pertuzumab dose that produces a steady-state concentration of ⩾20 *μ*g ml^−1^ in at least 90% of patients with HER2-positive aGC. The PK data show that, as expected, the 840 mg q3w dose resulted in higher pertuzumab concentrations overall than the 840/420 mg dose. The data demonstrate that both doses resulted in day 43 trough concentrations above the target of 20 *μ*g ml^−1^ in at least 90% of patients; however, the lower bound of the 95% CI in Arm A in the bootstrap analysis was 78.3%, suggesting a greater risk of not achieving the PK target in at least 90% of patients with the 840/420 mg pertuzumab dose and that the 840 mg q3w pertuzumab dose is more likely to maintain trough concentrations above the target in at least 90% of patients. Moreover, the 840 mg q3w pertuzumab dose produced trough concentrations in patients with HER2-positive aGC similar to those observed in HER2-positive MBC in CLEOPATRA, whereas the 840/420 mg dose produced lower trough concentrations. Exposure-response analysis of data from the ToGA trial in aGC showed that patients with the lowest trastuzumab serum trough concentrations had the highest rate of disease progression and shortest overall survival ([@bib45]; [@bib13]). Therefore, the 840 mg q3w pertuzumab dose is expected to provide greater treatment benefit than the 840/420 mg dose in patients with HER2-positive aGC.

Many population PK models have found patient demographic factors, such as age, body weight and gender, and also receptor number and disease-related factors, such as number of metastatic sites, circulating tumour receptors and tumour burden, to have a statistically significant impact on PK ([@bib9]; [@bib24]; [@bib47]). However, exploratory analysis did not show any apparent correlation between PK and these covariates in the small sample size of our study. Furthermore, no PK differences were observed between Asian and non-Asian patients, consistent with previous analyses ([@bib17]; [@bib10]; data not shown). As such, the reasons for the lower pertuzumab concentrations in aGC compared with MBC are currently unknown.

At this interim safety assessment, the combination of pertuzumab, trastuzumab and chemotherapy was well tolerated. The AE profiles were similar between arms and consistent with those observed with trastuzumab and chemotherapy in the ToGA trial ([@bib5]) with the exception of higher rates of diarrhoea.

Events of diarrhoea in JOSHUA were mostly grade 1--2 and occurred early during treatment, with their frequency decreasing during subsequent cycles, particularly following cycle 6. Diarrhoea was manageable and no patient discontinued study treatment due to this AE. Although more patients discontinued treatment in Arm B than Arm A (12 *vs* 8 patients), it is not clear whether this was due to the higher pertuzumab dose, as AEs leading to discontinuation were not uniform. As a pertuzumab dose of 1050 mg q3w has been shown to be safe and tolerable in phase I/II studies in a variety of solid tumour types ([@bib23]; [@bib4]; [@bib15]; [@bib3]; [@bib21]), the similarity of the safety profiles of the two doses in JOSHUA is not unexpected.

Preliminary data from the exploratory efficacy analysis show that patients with HER2-positive aGC treated with the combination of pertuzumab, trastuzumab, capecitabine and cisplatin achieved high rates of partial response (86% in Arm A and 55% in Arm B) or stable disease (14% in Arm A and 27% in Arm B) at the end of cycle 6. The overall response rates observed in JOSHUA compare favourably with that seen in patients with HER2-positive aGC treated with trastuzumab, capecitabine/fluorouracil and cisplatin in the ToGA trial (47% [@bib5]). Due to the small sample size and lack of a comparator arm in JOSHUA, no firm conclusions can be drawn about the activity of the study drug regimen or the difference between response rates in the two dose groups. However, results from JOSHUA support further investigation of dual blockade anti-HER2 therapy with pertuzumab plus trastuzumab in HER2-positive aGC.

In summary, a pertuzumab dose of 840 mg q3w in patients with HER2-positive aGC produces trough concentrations comparable to those seen in HER2-positive MBC without increasing the incidence of AEs. Therefore, the 840 mg q3w pertuzumab dose has been selected for an ongoing phase III study of first-line pertuzumab, trastuzumab and chemotherapy in HER2-positive metastatic gastric and gastro--oesophageal junction cancer (JACOB, NCT01774786; [@bib28]).
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![**Pertuzumab concentration--time profiles.** Pre-dose (trough) and post-dose (peak) mean (±s.d.) concentrations of pertuzumab are plotted against time for Arms A (closed circles) and B (open circles).](bjc2014356f1){#fig1}

![**Comparison of pertuzumab trough concentrations in JOSHUA (HER2-positive aGC) with CLEOPATRA (HER2-positive MBC).** Summary box-scatter plots of day 43 pertuzumab trough concentrations observed in JOSHUA and CLEOPATRA (pertuzumab arm). Black solid line=median; box limits=25th--75th percentiles; whiskers=1.5 × interquartile range; circles=individual concentrations; dotted line=20 *μ*g ml^−1^ target.](bjc2014356f2){#fig2}

![**Incidence of diarrhoea (all grades) at each treatment cycle.**](bjc2014356f3){#fig3}

###### Baseline patient characteristics

                                                    **Arm A: 840/420 mg pertuzumab,** ***n*****=15**   **Arm B: 840 mg q3w pertuzumab,** ***n*****=15**
  ------------------------------------------------- -------------------------------------------------- --------------------------------------------------
  **Age, years**                                                                                       
  Median (min--max)                                 67 (29--76)                                        59 (27--72)
  \<65, *n* (%)                                     6 (40.0)                                           10 (66.7)
  **Sex,** ***n*** **(%)**                                                                             
  Male                                              14 (93.3)                                          10 (66.7)
  **Ethnicity,** ***n*** **(%)**                                                                       
  Hispanic or Latino                                2 (13.3)                                           1 (6.7)
  Not Hispanic or Latino                            13 (86.7)                                          14 (93.3)
  **Race,** ***n*** **(%)**                                                                            
  Asian                                             9 (60.0)                                           8 (53.3)
  White                                             6 (40.0)                                           7 (46.7)
  **Weight, kg**                                                                                       
  Median (min--max)                                 67.0 (47.0--83.0)                                  66.8 (52.0--89.0)
  **Extent of disease on entry,** ***n*** **(%)**                                                      
  Metastatic                                        13 (86.7)                                          12 (80.0)
  Unresectable, locally advanced                    2 (13.3)                                           3 (20.0)
  **Primary site,** ***n*** **(%)**                                                                    
  Stomach                                           12 (80.0)                                          13 (86.7)
  Gastro--oesophageal junction                      3 (20.0)                                           2 (13.3)
  **Measurability,** ***n*** **(%)**                                                                   
  Measurable disease                                12 (80.0)                                          13 (86.7)
  Non-measurable evaluable disease only             3 (20.0)                                           2 (13.3)
  **Histologic subtypes,** ***n*** **(%)**                                                             
  Intestinal                                        6 (40.0)                                           5 (33.3)
  Diffuse                                           1 (6.7)                                            3 (20.0)
  Not known                                         8 (53.3)                                           7 (46.7)

###### Patient disposition

  ***n*** **(%)**                      **Arm A: 840/420 mg pertuzumab,** ***n*****=15**   **Arm B: 840 mg q3w pertuzumab,** ***n*****=15**
  ------------------------------------ -------------------------------------------------- --------------------------------------------------
  Completed six cycles of pertuzumab   14 (93.3)                                          11 (73.3)
  Still on treatment                   7 (46.7)                                           3 (20.0)
  Discontinued treatment               8 (53.3)                                           12 (80.0)
   Safety                              0 (0.0)                                            2 (13.3)
    Adverse event                      0 (0.0)                                            1 (6.7)
    Death                              0 (0.0)                                            1 (6.7)
   Non-safety                          8 (53.3)                                           10 (66.7)
    Physician decision                 0 (0.0)                                            1 (6.7)
    Progression of disease             8 (53.3)                                           8 (53.3)
    Withdrawal by patient              0 (0.0)                                            1 (6.7)

###### Grade **⩾**3 adverse events

  ***n*** **(%)**                               **Arm A: 840/420 mg pertuzumab,** ***n*****=15**   **Arm B: 840 mg q3w pertuzumab,** ***n*****=15**
  --------------------------------------------- -------------------------------------------------- --------------------------------------------------
  **Total number of patients with ⩾1 event**    14 (93.3)                                          12 (80.0)
  **Events occurring in ⩾3 patients overall**                                                      
  Neutropenia[a](#t3-fn1){ref-type="fn"}        8 (53.3)                                           5 (33.3)
  Anaemia                                       4 (26.7)                                           4 (26.7)
  Diarrhoea                                     4 (26.7)                                           4 (26.7)
  Decreased appetite                            2 (13.3)                                           5 (33.3)
  Febrile neutropenia                           4 (26.7)                                           2 (13.3)
  Fatigue                                       3 (20.0)                                           2 (13.3)
  Hypokalaemia                                  1 (6.7)                                            3 (20.0)
  Hyponatraemia                                 4 (26.7)                                           0 (0.0)
  Nausea                                        3 (20.0)                                           1 (6.7)
  Stomatitis                                    2 (13.3)                                           2 (13.3)
  Hypophosphataemia                             1 (6.7)                                            2 (13.3)
  Mucosal inflammation                          3 (20.0)                                           0 (0.0)

Covers terms 'neutropenia\' and 'neutrophil count decreased\'.

###### Overall response rate

  ***n*** **(%)**                                                   **Arm A: 840/420 mg pertuzumab, *n*=15**   **Arm B: 840 mg q3w pertuzumab, *n*=15**
  ----------------------------------------------------------------- ------------------------------------------ ------------------------------------------
  **Total number of patients with tumour assessment at baseline**   15 (100.0)                                 15 (100.0)
  **End of Cycle 3**                                                                                           
  *n*[a](#t4-fn1){ref-type="fn"}                                    15                                         12
  Partial response                                                  10 (66.7)                                  7 (58.3)
  Stable disease[b](#t4-fn2){ref-type="fn"}                         4 (26.7)                                   4 (33.3)
  Progressive disease                                               1 (6.7)                                    1 (8.3)
  **End of Cycle 6**                                                                                           
  *n*[a](#t4-fn1){ref-type="fn"}                                    14                                         11
  Partial response                                                  12 (85.7)                                  6 (54.5)
  Stable disease[b](#t4-fn2){ref-type="fn"}                         2 (14.3)                                   3 (27.3)
  Progressive disease                                               0 (0.0)                                    2 (18.2)

Percentages are based on *n* (number of patients with data available).

Three patients in Arm A and two patients in Arm B had non-measurable disease.
